Metabolomic analysis of rat serum in streptozotocin-induced diabetes and after treatment with oral triethylenetetramine (TETA)

Genome Medicine

Volumn 4, Issue 4, 2012, Pages

  Ugarte, Marta ^a   Brown, Marie ^a,b   Hollywood, Katherine A ^a,b   Cooper, Garth J ^a,b,c,d   Bishop, Paul N ^a,b   Dunn, Warwick B ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; BILE ACID; FATTY ACID; GLYCEROPHOSPHOLIPID; SPHINGOLIPID; STEROID; TRIENTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BILE ACID METABOLISM; BLOOD ANALYSIS; CONTROLLED STUDY; FOLLOW UP; GENETIC ANALYSIS; MALE; MASS SPECTROMETRY; METABOLOMICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; RAT; STREPTOZOCIN DIABETES; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

EID: 84860463899     PISSN: None     EISSN: 1756994X     Source Type: Journal    
DOI: 10.1186/gm334     Document Type: Article

References (62)

1. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998, 21:1414-1431. 10.2337/diacare.21.9.1414, 9727886.
2. Boyle JP, Honeycutt AA, Narayan KM, Hoerger TJ, Geiss LS, Chen H, Thompson TJ. Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S. Diabetes Care 2001, 24:1936-1940. 10.2337/diacare.24.11.1936, 11679460.
3. Oresic M, Simell S, Sysi-Aho M, Nanto-Salonen K, Seppanen-Laakso T, Parikka V, Katajamaa M, Hekkala A, Mattila I, Keskinen P, Yetukuri L, Reinikainen A, Lahde J, Suortti T, Hakalax J, Simell T, Hyoty H, Veijola R, Ilonen J, Lahesmaa R, Knip M, Simell O. Dysregulation of lipid and amino acid metabolism precedes islet autoimmunity in children who later progress to type 1 diabetes. J Exp Med 2008, 205:2975-2984. 10.1084/jem.20081800, 2605239, 19075291.
4. Trevisan R, Nosadini R, Avogaro A, Lippe G, Duner E, Fioretto P, Deana R, Tessari P, Tiengo A, Velussi M, Cernigoi A, Del Prato S, Crepaldi G. Type I diabetes is characterized by insulin resistance not only with regard to glucose, but also to lipid and amino acid metabolism. J Clin Endocrinol Metab 1986, 62:1155-1162. 10.1210/jcem-62-6-1155, 3517029.
5. Wang TJ, Larson MG, Vasan RS, Cheng S, Rhee EP, McCabe E, Lewis GD, Fox CS, Jacques PF, Fernandez C, O'Donnell CJ, Carr SA, Mootha VK, Florez JC, Souza A, Melander O, Clish CB, Gerszten RE. Metabolite profiles and the risk of developing diabetes. Nat Med 2011, 17:448-453. 10.1038/nm.2307, 3126616, 21423183.
6. Cahill GF. Insulin, diabetes and adipose tissue. A brief review. J Mich State Med Soc 1960, 59:1513-1518.
7. Li S, Shin HJ, Ding EL, van Dam RM. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2009, 302:179-188. 10.1001/jama.2009.976, 19584347.
8. Verrijn Stuart AA, Schipper HS, Tasdelen I, Egan DA, Prakken BJ, Kalkhoven E, de Jager W. Altered plasma adipokine levels and in vitro adipocyte differentiation in pediatric type 1 diabetes. J Clin Endocrinol Metab 2012, 97:463-472. 10.1210/jc.2011-1858, 22112811.
9. Cooper GJ, Chan YK, Dissanayake AM, Leahy FE, Keogh GF, Frampton CM, Gamble GD, Brunton DH, Baker JR, Poppitt SD. Demonstration of a hyperglycemia-driven pathogenic abnormality of copper homeostasis in diabetes and its reversibility by selective chelation: quantitative comparisons between the biology of copper and eight other nutritionally essential elements in normal and diabetic individuals. Diabetes 2005, 54:1468-1476. 10.2337/diabetes.54.5.1468, 15855335.
10. Dunn WB, Broadhurst DI, Atherton HJ, Goodacre R, Griffin JL. Systems level studies of mammalian metabolomes: the roles of mass spectrometry and nuclear magnetic resonance spectroscopy. Chem Soc Rev 2011, 40:387-426. 10.1039/b906712b, 20717559.
11. Dunn WB, Goodacre R, Neyses L, Mamas M. Integration of metabolomics in heart disease and diabetes research: current achievements and future outlook. Bioanalysis 2011, 3:2205-2222. 10.4155/bio.11.223, 21985415.
12. Gika HG, Theodoridis G, Extance J, Edge AM, Wilson ID. High temperature-ultra performance liquid chromatography-mass spectrometry for the metabonomic analysis of Zucker rat urine. J Chromatogr B Analyt Technol Biomed Life Sci 2008, 871:279-287. 10.1016/j.jchromb.2008.04.020, 18485837.
13. Connor SC, Hansen MK, Corner A, Smith RF, Ryan TE. Integration of metabolomics and transcriptomics data to aid biomarker discovery in type 2 diabetes. Mol Biosyst 2010, 6:909-921. 10.1039/b914182k, 20567778.
14. Katyare SS, Satav JG. Effect of streptozotocin-induced diabetes on oxidative energy metabolism in rat kidney mitochondria. A comparative study of early and late effects. Diabetes Obes Metab 2005, 7:555-562. 10.1111/j.1463-1326.2004.00429.x, 16050948.
15. Blachnio-Zabielska A, Zabielski P, Baranowski M, Gorski J. Effects of streptozotocin-induced diabetes and elevation of plasma FFA on ceramide metabolism in rat skeletal muscle. Horm Metab Res 2009, 42:1-7.
16. Srinivasan K, Ramarao P. Animal models in type 2 diabetes research: an overview. Indian J Med Res 2007, 125:451-472.
17. Zhang F, Ye C, Li G, Ding W, Zhou W, Zhu H, Chen G, Luo T, Guang M, Liu Y, Zhang D, Zheng S, Yang J, Gu Y, Xie X, Luo M. The rat model of type 2 diabetic mellitus and its glycometabolism characters. Exp Anim 2003, 52:401-407. 10.1538/expanim.52.401, 14625406.
18. Cooper GJ. Therapeutic potential of copper chelation with triethylenetetramine in managing diabetes mellitus and Alzheimer's disease. Drugs 2011, 71:1281-1320. 10.2165/11591370-000000000-00000, 21770477.
19. Lau AL, Failla ML. Urinary excretion of zinc, copper and iron in the streptozotocin-diabetic rat. J Nutr 1984, 114:224-233.
20. Cooper GJ, Phillips AR, Choong SY, Leonard BL, Crossman DJ, Brunton DH, Saafi L, Dissanayake AM, Cowan BR, Young AA, Occleshaw CJ, Chan YK, Leahy FE, Keogh GF, Gamble GD, Allen GR, Pope AJ, Boyd PD, Poppitt SD, Borg TK, Doughty RN, Baker JR. Regeneration of the heart in diabetes by selective copper chelation. Diabetes 2004, 53:2501-2508. 10.2337/diabetes.53.9.2501, 15331567.
21. Cooper GJ, Young AA, Gamble GD, Occleshaw CJ, Dissanayake AM, Cowan BR, Brunton DH, Baker JR, Phillips AR, Frampton CM, Poppitt SD, Doughty RN. A copper(II)-selective chelator ameliorates left-ventricular hypertrophy in type 2 diabetic patients: a randomised placebo-controlled study. Diabetologia 2009, 52:715-722. 10.1007/s00125-009-1265-3, 19172243.
22. Gong D, Lu J, Chen X, Reddy S, Crossman DJ, Glyn-Jones S, Choong YS, Kennedy J, Barry B, Zhang S, Chan YK, Ruggiero K, Phillips AR, Cooper GJ. A copper(II)-selective chelator ameliorates diabetes-evoked renal fibrosis and albuminuria, and suppresses pathogenic TGF-beta activation in the kidneys of rats used as a model of diabetes. Diabetologia 2008, 51:1741-1751. 10.1007/s00125-008-1088-7, 18636238.
23. Yoshii J, Yoshiji H, Kuriyama S, Ikenaka Y, Noguchi R, Okuda H, Tsujinoue H, Nakatani T, Kishida H, Nakae D, Gomez DE, De Lorenzo MS, Tejera AM, Fukui H. The copper-chelating agent, trientine, suppresses tumor development and angiogenesis in the murine hepatocellular carcinoma cells. Int J Cancer 2001, 94:768-773. 10.1002/ijc.1537, 11745476.
24. Mochida T, Tanaka T, Shiraki Y, Tajiri H, Matsumoto S, Shimbo K, Ando T, Nakamura K, Okamoto M, Endo F. Time-dependent changes in the plasma amino acid concentration in diabetes mellitus. Mol Genet Metab 2011, 103:406-409. 10.1016/j.ymgme.2011.05.002, 21636301.
25. Gerszten RE, Wang TJ. Two roads diverge: weight loss interventions and circulating amino acids. Sci Transl Med 2011, 3:80ps15. 10.1126/scitranslmed.3002377, 21525396.
26. Ashrafian H, Athanasiou T, Li JV, Bueter M, Ahmed K, Nagpal K, Holmes E, Darzi A, Bloom SR. Diabetes resolution and hyperinsulinaemia after metabolic Roux-en-Y gastric bypass. Obes Rev 2011, 12:e257-272. 10.1111/j.1467-789X.2010.00802.x, 20880129.
27. Shaham O, Wei R, Wang TJ, Ricciardi C, Lewis GD, Vasan RS, Carr SA, Thadhani R, Gerszten RE, Mootha VK. Metabolic profiling of the human response to a glucose challenge reveals distinct axes of insulin sensitivity. Mol Syst Biol 2008, 4:214. 2538910, 18682704.
28. Atherton HJ, Bailey NJ, Zhang W, Taylor J, Major H, Shockcor J, Clarke K, Griffin JL. A combined H-1-NMR spectroscopy- and mass spectrometry-based metabolomic study of the PPAR-alpha null mutant mouse defines profound systemic changes in metabolism linked to the metabolic syndrome. Physiol Genomics 2006, 27:178-186. 10.1152/physiolgenomics.00060.2006, 16868074.
29. Jorda A, Gomez M, Cabo J, Grisolia S. Effect of streptozotocin diabetes on some urea cycle enzymes. Biochem Biophys Res Commun 1982, 106:37-43. 10.1016/0006-291X(82)92054-X, 7103986.
30. Patterson AD, Bonzo JA, Li F, Krausz KW, Eichler GS, Aslam S, Tigno X, Weinstein JN, Hansen BC, Idle JR, Gonzalez FJ. Metabolomics reveals attenuation of the SLC6A20 kidney transporter in nonhuman primate and mouse models of type 2 diabetes mellitus. J Biol Chem 2011, 286:19511-19522. 10.1074/jbc.M111.221739, 21487016.
31. Jobgen WS, Fried SK, Fu WJ, Meininger CJ, Wu G. Regulatory role for the arginine-nitric oxide pathway in metabolism of energy substrates. J Nutr Biochem 2006, 17:571-588. 10.1016/j.jnutbio.2005.12.001, 16524713.
32. Wu G, Meininger CJ. Nitric oxide and vascular insulin resistance. Biofactors 2009, 35:21-27. 10.1002/biof.3, 19319842.
33. Leino M, Airaksinen MM. Methoxyindoles of the retina. Med Biol 1985, 63:160-169.
34. Prawitt J, Caron S, Staels B. Bile acid metabolism and the pathogenesis of type 2 diabetes. Curr Diab Rep 2011, 11:160-166. 10.1007/s11892-011-0187-x, 21431855.
35. Li T, Francl JM, Boehme S, Ochoa A, Zhang Y, Klaassen CD, Erickson SK, Chiang JY. Glucose and insulin induction of bile acid synthesis: mechanisms and implication in diabetes and obesity. J Biol Chem 2012, 287:1861-1873. 10.1074/jbc.M111.305789, 22144677.
36. Meissner M, Herrema H, van Dijk TH, Gerding A, Havinga R, Boer T, Muller M, Reijngoud DJ, Groen AK, Kuipers F. Bile acid sequestration reduces plasma glucose levels in db/db mice by increasing its metabolic clearance rate. PLoS One 2011, 6:e24564. 10.1371/journal.pone.0024564, 3210115, 22087215.
37. Beysen C, Murphy EJ, Deines K, Chan M, Tsang E, Glass A, Turner SM, Protasio J, Riiff T, Hellerstein MK. Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a randomised controlled study. Diabetologia 2012, 55:432-442. 10.1007/s00125-011-2382-3, 22134839.
38. Liu J, Jahn LA, Fowler DE, Barrett EJ, Cao W, Liu Z. Free fatty acids induce insulin resistance in both cardiac and skeletal muscle microvasculature in humans. J Clin Endocrinol Metab 2010, 96:438-446. 3048322, 21047922.
39. Altmaier E, Ramsay SL, Graber A, Mewes HW, Weinberger KM, Suhre K. Bioinformatics analysis of targeted metabolomics - uncovering old and new tales of diabetic mice under medication. Endocrinology 2008, 149:3478-3489. 10.1210/en.2007-1747, 18372322.
40. Fox TE, Bewley MC, Unrath KA, Pedersen MM, Anderson RE, Jung DY, Jefferson LS, Kim JK, Bronson SK, Flanagan JM, Kester M. Circulating sphingolipid biomarkers in models of type 1 diabetes. J Lipid Res 2010, 52:509-517. 3035687, 21068007.
41. Fox TE, Han X, Kelly S, Merrill AH, Martin RE, Anderson RE, Gardner TW, Kester M. Diabetes alters sphingolipid metabolism in the retina: a potential mechanism of cell death in diabetic retinopathy. Diabetes 2006, 55:3573-3580. 10.2337/db06-0539, 2141542, 17130506.
42. Lu J. Triethylenetetramine pharmacology and its clinical applications. Mol Cancer Ther 2010, 9:2458-2467. 10.1158/1535-7163.MCT-10-0523, 20660601.
43. Charlton M, Nair KS. Protein metabolism in insulin-dependent diabetes mellitus. J Nutr 1998, 128:323S-327S.
44. Smith OL, Wong CY, Gelfand RA. Skeletal muscle proteolysis in rats with acute streptozocin-induced diabetes. Diabetes 1989, 38:1117-1122. 10.2337/diabetes.38.9.1117, 2670642.
45. Kowluru RA, Koppolu P. Diabetes-induced activation of caspase-3 in retina: effect of antioxidant therapy. Free Radic Res 2002, 36:993-999. 10.1080/1071576021000006572, 12448825.
46. Vincent JA, Mohr S. Inhibition of caspase-1/interleukin-1beta signaling prevents degeneration of retinal capillaries in diabetes and galactosemia. Diabetes 2007, 56:224-230. 10.2337/db06-0427, 17192486.
47. Huster D, Lutsenko S. Wilson disease: not just a copper disorder. Analysis of a Wilson disease model demonstrates the link between copper and lipid metabolism. Mol Biosyst 2007, 3:816-824. 10.1039/b711118p, 18000558.
48. Durand E, Lecoeur C, Delplanque J, Benzinou M, Degraeve F, Boutin P, Marre M, Balkau B, Charpentier G, Froguel P, Meyre D. Evaluating the association of FAAH common gene variation with childhood, adult severe obesity and type 2 diabetes in the French population. Obes Facts 2008, 1:305-309.
49. Murdolo G, Kempf K, Hammarstedt A, Herder C, Smith U, Jansson PA. Insulin differentially modulates the peripheral endocannabinoid system in human subcutaneous abdominal adipose tissue from lean and obese individuals. J Endocrinol Invest 2007, 30:RC17-21.
50. Hianik T, Rybar P, Sikurova L, Hermetter A. Changes of compressibility of low density lipoproteins following copper mediated oxidation. Gen Physiol Biophys 2003, 22:139-149.
51. Bailey AL, Southon S. Determination of total long-chain fatty acids in human plasma and lipoproteins, before and during copper-stimulated oxidation, by high-performance liquid chromatography. Anal Chem 1998, 70:415-419. 10.1021/ac970585o, 9450368.
52. Maceyka M, Harikumar KB, Milstien S, Spiegel S. Sphingosine-1-phosphate signaling and its role in disease. Trends Cell Biol 2012, 22:50-60. 10.1016/j.tcb.2011.09.003, 22001186.
53. Laychock SG, Sessanna SM, Lin MH, Mastrandrea LD. Sphingosine 1-phosphate affects cytokine-induced apoptosis in rat pancreatic islet beta-cells. Endocrinology 2006, 147:4705-4712. 10.1210/en.2006-0456, 16794003.
54. Fox TE, Kester M. Therapeutic strategies for diabetes and complications: a role for sphingolipids?. Adv Exp Med Biol 2010, 688:206-216. 10.1007/978-1-4419-6741-1_14, 20919656.
55. Geoffroy K, Troncy L, Wiernsperger N, Lagarde M, El Bawab S. Glomerular proliferation during early stages of diabetic nephropathy is associated with local increase of sphingosine-1-phosphate levels. FEBS Lett 2005, 579:1249-1254. 10.1016/j.febslet.2004.12.094, 15710421.
56. Nikolova-Karakashian MN, Reid MB. Sphingolipid metabolism, oxidant signaling, and contractile function of skeletal muscle. Antioxid Redox Signal 2011, 15:2501-2517. 10.1089/ars.2011.3940, 21453197.
57. Dunn WB, Broadhurst D, Begley P, Zelena E, Francis-McIntyre S, Anderson N, Brown M, Knowles JD, Halsall A, Haselden JN, Nicholls AW, Wilson ID, Kell DB, Goodacre R. Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. Nat Protoc 2011, 6:1060-1083. 10.1038/nprot.2011.335, 21720319.
58. Dunn WB, Broadhurst D, Brown M, Baker PN, Redman CWG, Kenny LC, Kell DB. Metabolic profiling of serum using Ultra Performance Liquid Chromatography and the LTQ-Orbitrap mass spectrometry system. J Chromatogr B 2008, 871:288-298.
59. MathWorks. , http://www.mathworks.com/
60. Sumner LW, Amberg A, Barrett D, Beale MH, Beger R, Daykin CA, Fan TWM, Fiehn O, Goodacre R, Griffin JL, Hankemeier T, Hardy N, Harnly J, Higashi R, Kopka J, Lane AN, Lindon JC, Marriott P, Nicholls AW, Reily MD, Thaden JJ, Viant MR. Proposed minimum reporting standards for chemical analysis. Metabolomics 2007, 3:211-221.
61. Brown M, Wedge DC, Goodacre R, Kell DB, Baker PN, Kenny LC, Mamas MA, Neyses L, Dunn WB. Automated workflows for accurate mass-based putative metabolite identification in LC/MS-derived metabolomic datasets. Bioinformatics 2011, 27:1108-1112. 10.1093/bioinformatics/btr079, 21325300.
62. Brown M, Dunn WB, Dobson P, Patel Y, Winder CL, Francis-McIntyre S, Begley P, Carroll KM, Broadhurst D, Tseng A, Swainston N, Spasic I, Goodacre R, Kell DB. Mass spectrometry tools and metabolite-specific databases for molecular identification in metabolomics. Analyst 2009, 134:1322-1332. 10.1039/b901179j, 19562197.